ArticleFrontiers in cellular neuroscience2016
Serum S100B Protein is Specifically Related to White Matter Changes in Schizophrenia.
Article in Frontiers in cellular neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- From case-control averages to validated subgroups: Interpreting inflammatory and neuroaxonal-injury biomarkers in schizophrenia and major depression.Brain, behavior, & immunity - health · 2026Review
- Machine learning helps predict early onset psychosis with serum protein biomarkers, neuropsychometry, and clinicodemographic data.Scientific reports · 2025Article
- Salivary Biomarkers as a Predictive Factor in Anxiety, Depression, and Stress.Current issues in molecular biology · 2025Review
- Peripheral S100B Protein Levels in Five Major Psychiatric Disorders: A Systematic Review.Brain sciences · 2023Review
- Vascular-related biomarkers in psychosis: a systematic review and meta-analysis.Frontiers in psychiatry · 2023Review
- Systematic Review and Meta-Analysis of Damage Associated Molecular Patterns HMGB1 and S100B in Schizophrenia.Psychiatry investigation · 2022Article
- Correlation of BDNF, VEGF, TNF-α, and S100B with cognitive impairments in chronic, medicated schizophrenia patients.Neuropsychopharmacology reports · 2022Article
- Schizophrenia and Alarmins.Medicina (Kaunas, Lithuania) · 2022Review
- Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia.Behavioural brain research · 2021Review
- MMP9/RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory/excitatory imbalance: a reverse translation study in schizophrenia patients.Molecular psychiatry · 2020Article
- Blood-brain barrier pathology in patients with severe mental disorders: a systematic review and meta-analysis of biomarkers in case-control studies.Brain, behavior, & immunity - health · 2020Article
- Racial Differences in S100b Levels in Persons with Schizophrenia.The Psychiatric quarterly · 2020Article
- Longitudinal serum S100β and brain aging in the Lothian Birth Cohort 1936.Neurobiology of aging · 2018Article
- Brain vascular heterogeneity: implications for disease pathogenesis and design of in vitro blood-brain barrier models.Fluids and barriers of the CNS · 2018Review
- Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features.Journal of molecular neuroscience : MN · 2018Article
- Antibiotic-induced dysbiosis of the microbiota impairs gut neuromuscular function in juvenile mice.British journal of pharmacology · 2017Article
- White matter damage after traumatic brain injury: A role for damage associated molecular patterns.Biochimica et biophysica acta. Molecular basis of disease · 2017Review
- Correlation between serum S100β protein levels and cognitive dysfunction in patients with cerebral small vessel disease: a case-control study.Bioscience reports · 2017Article
- Neurovascular Unit Dysfunction and Blood-Brain Barrier Hyperpermeability Contribute to Schizophrenia Neurobiology: A Theoretical Integration of Clinical and Experimental Evidence.Frontiers in psychiatry · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia can be conceptualized as a form of dysconnectivity between brain regions.To investigate the neurobiological foundation of dysconnectivity, one approach is to analyze white matter structures, such as the pathology of fiber tracks. S100B is considered a marker protein for glial cells, in particular oligodendrocytes and astroglia, that passes the blood brain barrier and is detectable in peripheral blood. Earlier Studies have consistently reported increased S100B levels in schizophrenia. In this study, we aim to investigate associations between S100B and structural white matter abnormalities.
methodsWe analyzed data of 17 unmedicated schizophrenic patients (first and recurrent episode) and 22 controls. We used voxel based morphometry (VBM) to detect group differences of white matter structures as obtained from T1-weighted MR-images and considered S100B serum levels as a regressor in an age-corrected interaction analysis.
resultsS100B was increased in both patient subgroups. Using VBM, we found clusters indicating significant differences of the association between S100B concentration and white matter. Involved anatomical structures are the posterior cingulate bundle and temporal white matter structures assigned to the superior longitudinal fasciculus.
conclusionsS100B-associated alterations of white matter are shown to be existent already at time of first manifestation of psychosis and are distinct from findings in recurrent episode patients. This suggests involvement of S100B in an ongoing and dynamic process associated with structural brain changes in schizophrenia. However, it remains elusive whether increased S100B serum concentrations in psychotic patients represent a protective response to a continuous pathogenic process or if elevated S100B levels are actively involved in promoting structural brain damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.